RVXCF up 19.41% in October so far..... On the
Post# of 144494
Posted On: 10/05/2016 6:26:23 PM
RVXCF up 19.41% in October so far.....
On the TSX (Canada's big board exchange) it ran into the bell and closed at $2.47 CDN which = $1.87 USD at current conversion rates, so it might gap up on the OTC tomorrow.
Anyone interested in doing some DD I have written several blog pieces about it at AvoidTheBag going back to June when it was trading around $1.30 CDN.
I also moderate the RVXCF forum here at IH and would welcome anyone wanted to post questions or commentary.
As I've mentioned before Resverlogix is a biotech engaged in the relatively new field of Epigentics. Everyone knows what Genes are, and Epi is Latin and means above. So in a nutshell Epigenetics is the level above Genetics and it involves writers and erasers, turning things on and off. Think of Genetics as hardware and Epigenetics as software.
The company's lead compound is RVX 208 and it has been named Apabetalone. Apabetalone has been trough pre clinical trials as well as Phase I and Phase II.....they're now in Phase III with a trial called BETonMACE the goal of which is to prove that Apabetalone will reduce the incidence of Major Adverse Cardiac Events in patients with full blown insulin dependent Diabetes, otherwise known as Diabetes Mellitus.
Is it a slam dunk sure thing? No....obviously not, there is no such thing. Fortunately the independent Data Safety Monitoring Board that is overseeing the BETonMACE trial, they just gave the company a positive recommendation on continuing the trial in August citing no safety of efficacy concerns....The trial started dosing patients in Oct/Nov of 2015.
They have major financial backing from Eastern Capital, which is the investment arm of well known Billionaire Kenneth Dart.
One to keep an eye on in any case imo....
On the TSX (Canada's big board exchange) it ran into the bell and closed at $2.47 CDN which = $1.87 USD at current conversion rates, so it might gap up on the OTC tomorrow.
Anyone interested in doing some DD I have written several blog pieces about it at AvoidTheBag going back to June when it was trading around $1.30 CDN.
I also moderate the RVXCF forum here at IH and would welcome anyone wanted to post questions or commentary.
As I've mentioned before Resverlogix is a biotech engaged in the relatively new field of Epigentics. Everyone knows what Genes are, and Epi is Latin and means above. So in a nutshell Epigenetics is the level above Genetics and it involves writers and erasers, turning things on and off. Think of Genetics as hardware and Epigenetics as software.
The company's lead compound is RVX 208 and it has been named Apabetalone. Apabetalone has been trough pre clinical trials as well as Phase I and Phase II.....they're now in Phase III with a trial called BETonMACE the goal of which is to prove that Apabetalone will reduce the incidence of Major Adverse Cardiac Events in patients with full blown insulin dependent Diabetes, otherwise known as Diabetes Mellitus.
Is it a slam dunk sure thing? No....obviously not, there is no such thing. Fortunately the independent Data Safety Monitoring Board that is overseeing the BETonMACE trial, they just gave the company a positive recommendation on continuing the trial in August citing no safety of efficacy concerns....The trial started dosing patients in Oct/Nov of 2015.
They have major financial backing from Eastern Capital, which is the investment arm of well known Billionaire Kenneth Dart.
One to keep an eye on in any case imo....
(0)
(0)
Check out my blog if you like: Avoid The Bag
Scroll down for more posts ▼